Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239182 · ClinicalTrials.gov registry record · Phase 2
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Anwaar Saeed.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05239182 is a Phase 2 study that was terminated before completion, run by Anwaar Saeed. The registered enrollment target is 7 participants.
The verdict
NCT05239182, a Phase 2 study, was terminated before completion, sponsored by Anwaar Saeed.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.
Interventions
- DRUG Retifanlimab
- DRUG Gemcitabine
- DRUG Abraxane
- DRUG 9-ING-41
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2024-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05239182
The ClinicalTrials.gov registry entry for NCT05239182 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anwaar Saeed, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Retifanlimab is the first listed.
NCT05239182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05239182 about?
NCT05239182 is a clinical study titled "9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma". This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.
What is the current status of trial NCT05239182?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2022-01-26. Estimated completion is 2024-02-04.
What interventions are being tested in trial NCT05239182?
The interventions under investigation include: Retifanlimab (DRUG), Gemcitabine (DRUG), Abraxane (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT05239182?
This trial is sponsored by Anwaar Saeed, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.